AFMD Stock Forecast 2025-2026
Distance to AFMD Price Targets
AFMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Affimed (AFMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AFMD and similar high-potential opportunities.
Latest AFMD Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, AFMD has a bullish consensus with a median price target of $11.27 (ranging from $5.12 to $25.66). Currently trading at $0.83, the median forecast implies a 1,260.2% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AFMD Analyst Ratings
AFMD Price Target Range
Latest AFMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AFMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 12, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $15.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $10.00 |
| Nov 19, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Nov 15, 2024 | Stifel | Bradley Canino | Hold | Maintains | $4.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $10.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $10.00 |
| Jun 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $10.00 |
| Jun 13, 2024 | Laidlaw & Co. | Yale Jen | Buy | Maintains | $25.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $10.00 |
| Apr 1, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Apr 1, 2024 | Stifel | Bradley Canino | Hold | Maintains | $5.00 |
| Apr 1, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $25.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $10.00 |
| Nov 15, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
| Sep 25, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $7.00 |
| Sep 12, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $7.00 |
| Sep 7, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $7.00 |
| Aug 11, 2023 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $6.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
Affimed N.V. (AFMD) Competitors
The following stocks are similar to Affimed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Affimed N.V. (AFMD) Financial Data
Affimed N.V. has a market capitalization of $13.58M with a P/E ratio of -0.1x. The company generates $6.06M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -91.6% quarter-over-quarter, while maintaining an operating margin of -8,709.1% and return on equity of -149.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Affimed N.V. (AFMD) Business Model
About Affimed N.V.
Develops targeted cancer therapies using immuno-oncology.
Affimed N.V. operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. The company generates revenue primarily through partnerships, collaborations, and potential future sales of its proprietary bispecific antibodies and innate cell engagers that target various cancer types.
Headquartered in Heidelberg, Germany, Affimed collaborates with academic institutions and industry partners to enhance drug development. Its ROCK platform is central to its research, enabling the development of therapies that harness the body's immune system to combat cancer.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Dr. Andreas Harstrick M.D.
Country
Germany
IPO Year
2014
Website
www.affimed.comAffimed N.V. (AFMD) Latest News & Analysis
Affimed N.V. CEO Dr. Shawn Leland will speak at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 2:20 p.m. EDT.
Dr. Leland's participation in a major healthcare conference highlights Affimed's visibility and potential, which may influence investor sentiment and stock performance.
Affimed N.V. will hold a conference call on December 17 at 8:30 a.m. EST to discuss clinical data from its AFM24-102 trial for non-small cell lung cancer.
The upcoming conference call on clinical data for AFM24-102 may influence investor sentiment and stock volatility, as positive results could enhance Affimed's market position in immuno-oncology.
Affimed N.V. presented data at the 66th ASH Annual Meeting from its LuminICE-203 study involving 22 patients, evaluating the combination of AFM13 and AlloNK® for treating R/R cHL.
Data presentation at a major oncology conference can boost Affimed's visibility and credibility, potentially attracting investors and influencing stock performance based on trial outcomes.
Affimed N.V. presented promising Phase 1 study data on AFM28 for R/R AML at the 66th ASH Annual Meeting, showing clinical efficacy and a manageable safety profile at 300 mg weekly.
Positive clinical data for AFM28 in treating R/R AML can boost Affimed's stock price, attract investment, and enhance its reputation in the competitive biotech sector.
A treatment for Relapsed/Refractory Hodgkin Lymphoma has shown an 83.3% overall response rate and a 50% complete response rate, with a well-managed safety profile.
Strong early efficacy data in a cancer treatment may indicate significant growth potential for the company, impacting stock prices and attracting investor interest in biopharmaceuticals.
The FDA granted a Regenerative Medicine Advanced Therapy designation to Affimed's acimtamig with AlloNK for Hodgkin lymphoma treatment, but shares declined following the news.
The FDA's designation can boost future prospects, but falling shares may reflect investor concerns about competition, efficacy, or regulatory hurdles affecting Affimed's product.
Frequently Asked Questions About AFMD Stock
What is Affimed N.V.'s (AFMD) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Affimed N.V. (AFMD) has a median price target of $11.27. The highest price target is $25.66 and the lowest is $5.12.
Is AFMD stock a good investment in 2025?
According to current analyst ratings, AFMD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AFMD stock?
Wall Street analysts predict AFMD stock could reach $11.27 in the next 12 months. This represents a 1,260.2% increase from the current price of $0.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Affimed N.V.'s business model?
Affimed N.V. operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. The company generates revenue primarily through partnerships, collaborations, and potential future sales of its proprietary bispecific antibodies and innate cell engagers that target various cancer types.
What is the highest forecasted price for AFMD Affimed N.V.?
The highest price target for AFMD is $25.66 from at , which represents a 2,997.1% increase from the current price of $0.83.
What is the lowest forecasted price for AFMD Affimed N.V.?
The lowest price target for AFMD is $5.12 from at , which represents a 518.3% increase from the current price of $0.83.
What is the overall AFMD consensus from analysts for Affimed N.V.?
The overall analyst consensus for AFMD is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.27.
How accurate are AFMD stock price projections?
Stock price projections, including those for Affimed N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
